Nonviral CRISPR/Cas9 mutagenesis for streamlined generation of mouse lung cancer models.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 38959035.
- Also identified by DOI 10.1073/pnas.2322917121 and PMC identifier 11252735.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Functional analysis in mouse models is necessary to establish the involvement of a set of genetic variations in tumor development. A modeling platform to facilitate and cost-effectively analyze the role of multiple genes in carcinogenesis would be valuable. Here, we present an innovative strategy for lung mutagenesis using CRISPR/Cas9 ribonucleoproteins delivered via cationic polymers. This approach allows the simultaneous inactivation of multiple genes. We validate the effectiveness of this system by targeting a group of tumor suppressor genes, specifically <i>Rb1</i>, <i>Rbl1</i>, <i>Pten</i>, and <i>Trp53</i>, which were chosen for their potential to cause lung tumors, namely small cell lung carcinoma (SCLC). Tumors with histologic and transcriptomic features of human SCLC emerged after intratracheal administration of CRISPR/polymer nanoparticles. These tumors carried loss-of-function mutations in all four tumor suppressor genes at the targeted positions. These findings were reproduced in two different pure genetic backgrounds. We provide a proof of principle for simplified modeling of lung tumorigenesis to facilitate functional testing of potential cancer-related genes.
Medical subject headings
- Lung Neoplasms
- CRISPR-Cas Systems
- PTEN Phosphohydrolase
- Tumor Suppressor Protein p53
- Small Cell Lung Carcinoma
- Mutagenesis